Roche shelved these psychiatry drugs. So its former head of neuro cooked up some new plans — and raised $59M for his startup

As the former head of neuroscience product development at Roche for a decade, George Garibaldi can personally vouch for the quality of what the Swiss pharma giant does. But having worked on psychiatric disorders, he also knew way too well the downside of a field where animal models were a poor prediction of how drugs would perform in humans.